FMP
LadRx Corporation
CYTR
OTC
Inactive Equity
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
0.09 USD
-0.002 (-2.22%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
Description
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
CIK
0000799698
ISIN
US2328286081
CUSIP
232828608
Address
11726 San Vicente Blvd Ste 650
Phone
13108265648
Country
US
Employee
3
IPO Date
Nov 10, 1986
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
CYTR Financial Summary
CIK
0000799698
Exchange
OTC
Industry
Biotechnology
Sector
Healthcare
CUSIP
232828608
ISIN
US2328286081
Country
US
Price
0.09
Beta
2.1
Volume Avg.
0
Market Cap
0
Shares
-
52-Week
0.05-0.86
DCF
1.3
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.25
P/B
-
Website
https://www.cytrx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest CYTR News
It looks like there's no news available.
